Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 8,143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Melanoma
Interventions: Cyclophosphamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Muscle Weakness
Interventions: Magnetic Muscle Stimulation (MMS) device; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Pleasanton, California • Sacramento, California

Conditions: Healthy
Interventions: Midazolam, PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Ventral Hernia
Interventions: Retrospective chart review; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more

Conditions: Schizophrenia
Interventions: BI 409306, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more

Conditions: Aortic Valve Stenosis
Interventions: Exercise, Cognitive behavioral interventions, Attention control education program; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Parenteral Nutrition
Interventions: Sodium Glycerophosphate Injection, Sodium Phosphates Injection; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity, Overweight, Weight Loss, Diet Habit
Interventions: Weight Management Intervention; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: HIV-associated Neuropathy, Polyneuropathy
Interventions: SAB378, methadone, SAB placebo, Methadone placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Diego, California • Brooklyn, New York • Rochester, New York

Conditions: Substance Use Disorders
Interventions: Smartphone app; Device
Lead sponsor: BrightView LLC; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Cancer, SCLC
Interventions: Nivolumab, Plinabulin, Ipilimumab; Drug
Lead sponsor: Salma Sabbour; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Spinal Cord Injuries
Interventions: Low-force muscle stimulation, High-force muscle stimulation, Sequential low-force and high-force muscle stimulation; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 56 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Hiv
Interventions: Data to Suppression (D2S), Usual practice; Other
Lead sponsor: City University of New York; Other
Eligibility: Not listed
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Sitagliptin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas

Conditions: Venous Distension Reflex, Blood Pressure
Interventions: Wrist-to-elbow (W-E) occlusion, ketorolac tromethamine, saline control; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Fossa Ependymoma
Interventions: 5-Azacytidine and trastuzumab infusion; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Year to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes
Interventions: Diabetes behavior change skills training, Physical activity promotion program; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 13 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Healthy Subjects
Interventions: Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypophosphatasia
Interventions: ALXN1850, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Indianapolis, Indiana • Garden City, New York • Durham, North Carolina + 2 more

Conditions: Mental Disorders, Behavior Disorders
Interventions: Recovery Roadmap (RR) Wave 1, Recovery Roadmap (RR) Wave 2; Behavioral
Lead sponsor: Center for Social Innovation, Massachusetts; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Needham, Massachusetts

Search by objective public record fields.

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

Magnetic Muscle Stimulation of Abdominal Muscle

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Home-Based Exercise Program For Recovery After Transcatheter Aortic Valve Replacement

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

Individualized Diet Improvement Program for Weight Loss and Maintenance, Cohort 2

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

Contingency Management Using Smartphone App in Patients With SUD

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Novel Intervention to Influence Muscle Plasticity in Veterans

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

Autonomic Control of the Circulation and VDR

Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma

Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Recovery Roadmap Phase II Small Business Innovation Research Grant